Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

“Outside of clean water, vaccines are one of the greatest innovations of all time in public health according to the World ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire U.S.-based SpringWorks Therapeutics for approximately ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...